Dossier assessment
Burosumab (X-linked hypophosphataemia, 1 month to 1 year) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Burosumab (X-linked hypophosphataemia, 1 month to 1 year) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Burosumab (X-linked hypophosphataemia, 1 month to 1 year) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Treatment of X-linked hypophosphataemia (XLH) in infants from 1 month to 1 year of age with hypophosphataemia
Added benefit not proven
Project details
- Project no.
- A26-74
- Commission
- Commission awarded on 23.06.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A26-74_en
Connected Projects
-
Dossier assessment
Burosumab (X-linked hypophosphataemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Burosumab (X-linked hypophosphataemia, = 18 years) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Burosumab (FGF23-related hypophosphataemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed